Antiendotoxin monoclonal antibodies. What future now?
Susla
G M
GM
Pharmacy Department, National Institutes of Health, Bethesda, Maryland.
Dew
R B
RB
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D004311:Double-Blind Method; D004731:Endotoxins / Q000737:chemistry / Q000276:immunology* / Q000378:metabolism; D006090:Gram-Negative Bacteria / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D006801:Humans; D018805:Sepsis / Q000209:etiology / Q000276:immunology / Q000628:therapy*; D014481:United States; D014486:United States Food and Drug Administration
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D004731:Endotoxins; C071470:edobacomab; C068069:nebacumab